98%
921
2 minutes
20
The Impella 5.5 (Abiomed) is a percutaneous, temporary left ventricular assist device (LVAD) that serves as an important method of treatment of acute cardiogenic shock refractory to medical management. The Impella 5.5 and 5.0 are commonly inserted through the right axillary artery; however, this may be limited by inadequate vessel diameter to accommodate the Impella and inadequate vessel quality. A central approach to Impella 5.5 incision has been described in the pediatric population, particularly via the innominate artery through a suprasternal and/or neck incision, with success. As an alternative to axillary Impella placement, we propose the usage of a limited suprasternal incision for Impella 5.5 insertion in the adult population, either through the proximal right subclavian artery or the distal innominate artery. This may offer multiple advantages, such as increased vessel diameter and quality of more proximal vessels, avoidance of partial sternotomy, avoidance of a second infraclavicular wound site if the patient progresses to require LVAD or transplant, avoidance of lymphatic and nerve injury through the axillary exposure, ease of manipulation for repositioning, and patient rehabilitation. Potential limitations include difficulty due to body habitus, potential risk of stroke with the innominate approach, and wound complications. A central approach is a reasonable alternative to axillary Impella placement in patients with inadequate axillary artery caliber, defined as less than 6-7 mm diameter, poor artery quality to accommodate anastomosis, and small body habitus, allowing for ease of exposure.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11045705 | PMC |
http://dx.doi.org/10.1007/s12055-024-01699-5 | DOI Listing |
ESC Heart Fail
September 2025
Division of Heart Failure and Transplant, Mayo Clinic in Florida, Jacksonville, Florida, USA.
Background: Patients with end-stage heart failure and chronic kidney disease requiring dual-organ transplantation (DOT) face significant challenges in utilizing durable mechanical circulatory support due to the risks associated with renal replacement therapies (RRTs) and multi-organ failure. Given the limited options available for long-term support in this patient population, there remains a critical need for alternative strategies to optimize end-organ function and bridge patients safely to transplant. With prolonged waitlist times for DOT, we present our experience with the Impella 5.
View Article and Find Full Text PDFCureus
August 2025
Internal Medicine, Baptist Memorial Hospital-North Mississippi, Oxford, USA.
Fulminant myocarditis is a rare but life-threatening complication of influenza A infection that can result in acute biventricular failure leading to cardiogenic shock. Here, we present the case of a young patient who developed acute bilateral heart failure secondary to influenza A and was successfully stabilized using both right and left-sided Impella devices. This case highlights the critical role of early and aggressive mechanical circulatory support (MCS) in managing fulminant myocarditis and emphasizes the utility of Impella in cases of severe cardiac dysfunction.
View Article and Find Full Text PDFJ Pharm Pract
September 2025
Ohio Health Riverside Methodist Hospital, Columbus, OH, USA.
PurposeTo describe the utilization of an on-call critical care pharmacist to bridge gaps in clinical coverage for subspecialized critically ill populations.MethodsIn October 2022, a 24/7 on-call team of medical and cardiac ICU pharmacists was established to field questions regarding patients with mechanical circulatory support and pulmonary hypertension. On-call pharmacists were available via centralized telephone number Monday through Friday from 4:00 p.
View Article and Find Full Text PDFThorac Cardiovasc Surg Rep
January 2025
Division of Cardiovascular Surgery, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States.
Cardiogenic shock in the setting of a ruptured papillary muscle can be extremely challenging to manage. We report two cases of successful and safe hemodynamic optimization with a modern axial-flow temporary left ventricular assist device, the Impella 5.5, prior to mitral valve replacement for this indication.
View Article and Find Full Text PDFBMC Anesthesiol
September 2025
Department of Cardiovascular Surgery, Justus-Liebig University Hospital, Rudolf-Buchheim Str. 7, Giessen, 35392, Germany.
Background: The implantation of a Swan-Ganz catheter for invasive hemodynamic monitoring is an established measure after cardiac surgery. A rare but serious complication is the formation of a knot in the heart, which can be diagnostically challenging. We report on a patient who developed left heart failure postoperatively after quadruple bypass surgery combined with aortic valve replacement and in whom a knot formed inadvertently during monitoring using a Swan-Ganz catheter.
View Article and Find Full Text PDF